Immunomet Therapeutics Inc.
USPTO PatentsView assignee record - 17 granted patents across 6 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Immunomet ranks #16,879 of 49,997 tracked US assignees by granted-patent volume, with 17 patents across 6 technology areas.
- #16,879
- of 49,997 US assignees by volume
- 24th percentile
- by Innovation Score (27.6/100)
- 8.2
- avg claims per patent
- -55%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R16879 · US Corporation #16,879 · 17 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 17 grants
- MID-PACK #16,879/49,997
- PHOTO-FINISH I-pex
- CPC-NARROW A61P · 6 areas
- INNOV-THIN 27.6/100
- CLAIMS-PAR 8.2 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -55% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: I-pex Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Immunomet’s 27.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Immunomet
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Immunomet Therapeutics · this assignee 28
Immunomet Therapeutics · this assignee
28 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Immunomet's Innovation Score is 27.6/100 (24th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Immunomet?
Each dot is one of Immunomet’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Immunomet’s own 8.2 claims/patent is at or below the 15.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Immunomet's grants concentrate
Immunomet Therapeutics Inc. is a focused PatentsView assignee: 6 CPC subclasses with 76.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (3 grants) versus a trough of 1 in 2022. By volume, Immunomet sits between I-pex Inc. and Innertron, Inc..
Immunomet's three-year grant acceleration
Immunomet Therapeutics Inc. shows 3 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Immunomet's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- I-pex
I-pex Inc.
17 patents
- IBS of America
IBS of America
17 patents
- Ildong Pharmaceut…
Ildong Pharmaceutical Co., Ltd.
17 patents
- Image Match Design
Image Match Design Inc.
17 patents
- IMS Health Incorp…
IMS Health Incorporated
17 patents
- Infinitt Healthca…
Infinitt Healthcare Co., Ltd.
17 patents
- Inivata
Inivata Ltd
17 patents
- Innertron
Innertron, Inc.
17 patents
- Immunomet Therape… ◀
Immunomet Therapeutics Inc.
17 patents
What this shows Immunomet holds 17 patents at rank #16,876, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Immunomet
By rank, the assignees closest to #16,876 in granted patent volume.
- I-pex Inc. #16,872 · 17 patents
- IBS of America #16,873 · 17 patents
- Ildong Pharmaceutical Co., Ltd. #16,874 · 17 patents
- Image Match Design Inc. #16,875 · 17 patents
- IMS Health Incorporated #16,877 · 17 patents
- Infinitt Healthcare Co., Ltd. #16,878 · 17 patents
- Inivata Ltd #16,879 · 17 patents
- Innertron, Inc. #16,880 · 17 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Immunomet's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Immunomet's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
28 24th percentile higher than 24% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 3 | 17.6% |
| 2017 | 2 | 11.8% |
| 2018 | 3 | 17.6% |
| 2019 | 3 | 17.6% |
| 2020 | 2 | 11.8% |
| 2022 | 1 | 5.9% |
| 2023 | 2 | 11.8% |
| 2025partial year | 1 | 5.9% |
Which technologies does Immunomet Therapeutics Inc. patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Immunomet Therapeutics Inc.'s patent record in context - here's where to go next.
- Immunomet Therapeutics Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 76.5% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #16,879 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Immunomet Therapeutics Inc. against I-pex Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 27.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.